March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a biopharmaceutical company, today reported fourth ...

Kronos Worldwide, Inc. KRO reported fourth-quarter 2024 loss of 12 cents per share, wider than a loss of 5 cents per share a year ago. The Zacks Consensus Estimate was earnings of 11 cents per share.

AlphaQuest LLC decreased its stake in Kronos Worldwide, Inc. (NYSE:KRO – Free Report) by 92.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange ...